Why did Abbott's shares fall 2% before the bell despite beating quarterly profit and revenue estimates?

Abbott's shares fell 2% before the bell because the company announced its 2026 profit forecast would be reduced by 20 cents per share due to the $23 billion acquisition of Exact Sciences, lowering the adjusted profit per share guidance to $5.38–$5.58 from the previous $5.55–$5.80 range.

How did Abbott's acquisition of Exact Sciences impact its first-quarter financial results and 2026 outlook?

The acquisition of Exact Sciences partially helped Abbott marginally beat Wall Street estimates for first-quarter profit ($1.15 vs. $1.14 expected) and revenue ($11.16 billion vs. $11 billion expected), but it also caused a 20-cent-per-share reduction in Abbott's 2026 adjusted profit forecast due to integration costs and dilution associated with the $23 billion deal.

Abbott Results Beat on Medical Device Boost, Exact Sciences Deal Hits Forecast

Apr 16, 2026

Abbott exceeded quarterly profit and revenue expectations driven by its medical device unit, though shares fell after lowering its 2026 profit forecast by 20 cents per share due to the $23 billion Exact Sciences acquisition.

reuters

2026-04-16

Abbott Results Beat on Medical Device Boost, Exact Sciences Deal Hits Forecast

2026-07-16

Abbott Raises 2026 Profit Forecast on Diagnostics, Heart Devices Strength

Abbott Results Beat on Medical Device Boost, Exact Sciences Deal Hits Forecast

FAQ